| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | GAL7; LGALS7A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human LGALS7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LGALS7(galectin-7)抗体的3篇模拟参考文献示例(注：以下内容为示例，非真实文献)：
---
1. **文献名称**: *Galectin-7 as a potential biomarker for squamous cell carcinoma*
**作者**: Kimura T, et al.
**摘要**: 该研究通过开发高特异性LGALS7抗体，发现galectin-7在皮肤鳞状细胞癌组织中显著高表达，且与肿瘤侵袭性相关。抗体用于免疫组化分析，提示其可能作为诊断标志物。
2. **文献名称**: *Anti-LGALS7 antibody modulates T-cell response in chronic inflammation*
**作者**: Leclerc M, et al.
**摘要**: 研究利用小鼠模型验证了阻断性LGALS7抗体对炎症性肠病的影响，发现抗体通过抑制galectin-7介导的T细胞凋亡通路，减轻肠道炎症反应。
3. **文献名称**: *Development of a novel monoclonal antibody against galectin-7 for therapeutic targeting in breast cancer*
**作者**: Zhang Y, et al.
**摘要**: 文章报道了一种新型LGALS7单克隆抗体的开发，并证明其可通过抗体依赖性细胞毒性(ADCC)抑制乳腺癌细胞转移，为靶向治疗提供了实验依据。
---
**注意**：以上文献为示例，实际研究中请通过PubMed、Google Scholar等平台检索真实发表的论文。
LGALS7 antibody targets galectin-7. a member of the galectin family of β-galactoside-binding proteins encoded by the *LGALS7* gene. Galectin-7 is a 15 kDa protein containing a conserved carbohydrate recognition domain (CRD) and functions as a homodimer. It is primarily expressed in epithelial tissues, including skin, thymus, and mucosal surfaces, and plays roles in cell-cell adhesion, apoptosis, and immune regulation.
Galectin-7 is implicated in both physiological and pathological processes. It regulates keratinocyte differentiation in skin homeostasis and promotes apoptosis in damaged cells. However, its dysregulation is linked to cancer progression, acting as a tumor suppressor in some contexts (e.g., colorectal cancer) or a promoter of metastasis in others (e.g., lymphoma). LGALS7 antibodies are essential tools for studying these dual roles, enabling detection of galectin-7 expression via techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF).
Research using LGALS7 antibodies has highlighted its potential as a diagnostic or prognostic biomarker. Elevated galectin-7 levels correlate with aggressive tumor behavior in certain cancers, while reduced expression is observed in others. Additionally, galectin-7 interacts with extracellular matrix components and immune cells, suggesting roles in modulating tumor microenvironments. Ongoing studies explore its therapeutic targeting, emphasizing the antibody's utility in both basic research and clinical applications.
×
